Abigail (Lauterbach) Schmitz
Senior Associate
RA Capital Management
TechAtlas senior associate evaluating biotech opportunities and competitive landscapes.
DP
Bio
Professional summary
Derek DiRocco is a Partner at RA Capital Management. Based on RA Capital’s official team page, he works on both public and private investments and serves as a board director for companies including Acrivon, Bambusa Therapeutics, Evommune, Forward Therapeutics, Frontier Medicines, Mineralys, Rivus, Stipple Bio, and Syntelios. His prior investment landscape coverage included solid tumor oncology. Before investing, he completed postdoctoral research at Brigham and Women’s Hospital/Harvard Medical School focused on Wnt signaling in mouse models of kidney disease and research related to solid organ fibrosis. He holds a BA in Biology from Holy Cross College and a PhD in Pharmacology from the University of Washington.
Investment focus
Stage, sector, and overall fit
Stage
public healthcare companiesprivate healthcare companies
Sector
biotechnologylife sciencesdrug developmentoncologykidney disease biology
Thesis
Public and private healthcare and life sciences investmentsSolid tumor oncology landscapesBiotech companies developing therapeutics and related healthcare products
Notable companies
Selected portfolio companies the partner has backed
AcrivonBambusa TherapeuticsEvommuneForward TherapeuticsFrontier MedicinesMineralysRivusStipple BioSyntelios
How to approach
Framing and angles for outreach
Pitch framing
Best approached with a scientifically grounded healthcare or biotech opportunity, especially where deep disease-area diligence and public/private market context are relevant.
Personalization hooks
- 1Reference his board work across therapeutics-focused RA Capital portfolio companies.
- 2For oncology-related opportunities, mention alignment with his prior solid tumor oncology landscape work.
Background
Career, education, and skills
Career history
- RA Capital ManagementPartner
Education
- Not specified on LinkedInPh.D., Life Sciences (inferred from title)
Skills
Biotech investingOncologyCardiometabolicFDA regulatory advocacy
Other partners at RA Capital Management
12 more profiles
Adam Prince, MD
Senior Associate, Strategic Initiatives
RA Capital Management
RA Capital TechAtlas senior associate with cardiology and medical training.
Alana MacDonald, Ph.D.
Senior Associate
RA Capital Management
Senior TechAtlas associate focused on biotech diligence, landscapes, and portfolio strategy.
Alejandro Sevilla
Associate
RA Capital Management
Planetary Health associate focused on climate-tech landscapes and investment evaluation.
Alex Miller
Senior Associate, Venture
RA Capital Management
Venture senior associate focused on biotech diligence and portfolio strategy.
Alex T. Zhang
Vice President, Structured Capital
RA Capital Management
Structured Capital VP focused on healthcare and life-sciences credit investments.
Alexander Martinez-Forte
Director, Quantitative Research & Strategy
RA Capital Management
RA Capital director leading quantitative analyses for investment decisions and portfolio management.
Allison Harrigan
Senior Director Corporate Development
RA Capital Management
Raven corporate development leader focused on biotech company creation.
Alyssa Larson
Director, Healthcare Specialist - Investor Relations
RA Capital Management
TechAtlas director supporting healthcare diligence and investor relations.
Ami Thakrar, PhD
Associate
RA Capital Management
TechAtlas associate focused on biotech diligence and program strategy.
Anish K. More
Vice President, Corporate Development
RA Capital Management
Raven corporate-development VP focused on investment evaluation and NewCo creation.
Anurag Kondapalli
Principal
RA Capital Management
Principal investing across public and private healthcare technology and services companies.